Compounders Research Compare

Achieve Life Sciences, Inc.(ACHV)

Biotechnology · Bothell, WA

$7.01-0.23 (-3.18%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Bothell, WA

28 employees

www.achievelifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Andrew D. Goldberg

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T12:45:14.142Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:45:14.142Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 719,639,590
Total debt · period ending 2026-06-30: 14,948,000
Cash · period ending 2026-06-30: 47,958,000
TTM operating EBITDA · period ending 2026-06-30: -58,051,000

FMP input reference: c295c1623f78bdf77a886cf07ea1e6d336f06da24b8c95eb76ef4971c7c9c79e

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACHV EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ACHV Competitors' EV/EBITDA Ratio

Achieve Life Sciences, Inc.

Current

Market Cap

$719.64M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Collegium Pharmaceutical, Inc.

Market Cap

$709.33M

EV/EBITDA Ratio

2.84x

TTM Avg

4.78x

3Y Avg

5.46x

5Y Avg

7.57x

Helus Pharma Inc.

Market Cap

$707.86M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Anteris Technologies Global Corp.

Market Cap

$734.10M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Faeth Therapeutics, Inc.

Market Cap

$698.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Candel Therapeutics, Inc.

Market Cap

$749.55M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Annexon, Inc.

Market Cap

$688.14M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

4D Molecular Therapeutics, Inc.

Market Cap

$675.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Avalo Therapeutics, Inc.

Market Cap

$767.46M

EV/EBITDA Ratio

N/A

TTM Avg

867.40x

3Y Avg

862.35x

5Y Avg

862.35x

Attovia Therapeutics, Inc.

Market Cap

$774.32M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Achieve Life Sciences, Inc. (ACHV)	$719.64M	N/A	N/A	N/A	N/A
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.33M	2.84x	4.78x	5.46x	7.57x
Helus Pharma Inc. (HELP)vs ›	$707.86M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$734.10M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$698.60M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$749.55M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$688.14M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$675.41M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$767.46M	N/A	867.40x	862.35x	862.35x
Attovia Therapeutics, Inc. (ATTO)vs ›	$774.32M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics